|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
|
22028916 |
2011 |
|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, we showed that homozygous carriers for the T442C variant of the ARLTS1 gene (ADP-ribosylation factor-like tumour suppressor protein 1 or ARL11, located at 13q14) are associated with an increased risk for both unselected and familial PCa.
|
23940804 |
2013 |
|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Prostate cancer, familial
|
|
0.020 |
GeneticVariation
|
BEFREE |
This study provides strong confirmation of the important role of ARLTS1 Cys148Arg variant as a contributor in PCa predisposition and a potential marker for aggressive disease outcome.
|
22028916 |
2011 |
|
Prostate cancer, familial
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |
|
ovarian neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
ARLTS1 Cys148Arg revealed a significant association with an increased risk of familial OC compared with both sporadic cases and controls in a dose-dependent manner (P = 0.0031 and 0.012, respectively).
|
19509554 |
2009 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Cys148Arg and Trp149Stop variants in the tumour suppressor gene ARLTS1 predispose to familial breast cancer, suggesting that these variants might also contribute to colorectal carcinogenesis.
|
16488076 |
2006 |
|
melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
While ARLTS1 Trp149Stop did not influence melanoma risk (OR = 0.83, 95% CI = 0.37-1.88, p = 0.65), Cys148Arg revealed a statistically significant association with an increased risk for heterozygous carriers (OR = 1.43, 95% CI = 1.05-1.95, p = 0.02).
|
16646072 |
2006 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
ARLTS1 variants, especially Cys148Arg (T442C), increase susceptibility to different cancers, including PCa.
|
22028916 |
2011 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
|
22028916 |
2011 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, we showed that homozygous carriers for the T442C variant of the ARLTS1 gene (ADP-ribosylation factor-like tumour suppressor protein 1 or ARL11, located at 13q14) are associated with an increased risk for both unselected and familial PCa.
|
23940804 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Malignant neoplasm of ovary
|
|
0.010 |
GeneticVariation
|
BEFREE |
ARLTS1 Cys148Arg revealed a significant association with an increased risk of familial OC compared with both sporadic cases and controls in a dose-dependent manner (P = 0.0031 and 0.012, respectively).
|
19509554 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer.
|
17449901 |
2007 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Hereditary Prostate Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study provides strong confirmation of the important role of ARLTS1 Cys148Arg variant as a contributor in PCa predisposition and a potential marker for aggressive disease outcome.
|
22028916 |
2011 |
|
Hereditary Malignant Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |
|
Familial (FPAH)
|
|
0.020 |
GeneticVariation
|
BEFREE |
Both Cys148Arg and Trp149Stop were associated with an increased risk of familial or high-risk familial breast cancer, respectively.
|
16646072 |
2006 |
|
Familial (FPAH)
|
|
0.020 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs3803185 variant was not significantly associated with CRC risk in an external cohort (MCC-Spain), but it still showed some borderline significance in the pooled analysis of both cohorts (OR = 1.08, 95% CI = 0.98-1.18, P-value = 0.09, log-additive 0, 1, 2 alleles).
|
21819567 |
2011 |
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |